AR080987A1 - Formas cristalinas polimorficas a y d de la sal mesilato de 7-metil-5(3-piperazin-1-ilmetil-[1,2,4]oxadiazol-5-il)-2-(4-trifluorometoxibencil)2,3-dihidroisoindol-1-ona,metodo para prepararlas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento del dolor y la ansied - Google Patents

Formas cristalinas polimorficas a y d de la sal mesilato de 7-metil-5(3-piperazin-1-ilmetil-[1,2,4]oxadiazol-5-il)-2-(4-trifluorometoxibencil)2,3-dihidroisoindol-1-ona,metodo para prepararlas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento del dolor y la ansied

Info

Publication number
AR080987A1
AR080987A1 ARP110101484A ARP110101484A AR080987A1 AR 080987 A1 AR080987 A1 AR 080987A1 AR P110101484 A ARP110101484 A AR P110101484A AR P110101484 A ARP110101484 A AR P110101484A AR 080987 A1 AR080987 A1 AR 080987A1
Authority
AR
Argentina
Prior art keywords
oxadiazol
piperazin
methyl
salt
trifluorometoxibencil
Prior art date
Application number
ARP110101484A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR080987A1 publication Critical patent/AR080987A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Reivindicacion 2: La sal mesilato de 7-metil-5-(3-piperazin-1-ilmetil-[1,2,4]oxadiazol-5-il)-2-(4-trifluormetoxibencil)-2,3-dihidroisoindoI-1-ona, Polimorfo A, donde los valores d, 2-theta y los recuentos medidos por XRPD son: segun el cuadro (1) : 2-theta/s valor d recuentos (gamma = 1,5418L) 8,0, 11,1, 250; 17,8, 4,98,1932; 18,4, 4,81, 841; 19, 4,55,1471; 21,0, 4,22, 1841. Reivindicacion 3: La sal mesilato de 7-metil-5-(3-piperazin-1-ilmetil-[1,2,4]oxadiazol-5-il)-2(4-trifluormetoxibencil)-2,3-dihidroisoindol-1-ona, Polimorfo A, de acuerdo con la reivindicacion 2, donde los valores d, 2-theta y recuentos adicionales, medidos por XRPD, son como en cuadro (2): 2-theta/s valor d recuentos ( gamma = 1,5418L) 11,8, 7,5, 264; 15,6, 5,7, 465; 17,1, 5,2, 469; 20,4 4,35, 758; 21,3, 4,2 ,471. Reivindicacion 10: La sal mesilato de 7-metil-5-(3-piperazin-1-ilmetil-[1,2,4]oxadiazol-5-il)-2-(4-trifluormetoxibencil)-2,3-dihidroisoindol-1-ona, Polimorfo D, donde los valores d, 2-theta y los recuentos, medidos por XRPD, son: 2-theta/°, valor d, recuentos (gamma = 1,5418L) 10,9, 8,1 977; 15,8, 5,6, 766; 17,7, 5,0, 1003; 18,0, 4,93, 1056; 20,2, 4,39, 913. Reivindicacion 11: La sal mesilato de 7-metil-5-(3-piperazin-1-ilmetil-[1,2,4]oxadiazol-5-il)-2-(4-trifluormetoxibencil)-2,3-dihidroisoindol-1-ona, Polimorfo D, de acuerdo con la reivindicacion 2, donde los valores d, 2-theta y recuentos adicionales, medidos por XRPD, son: 2-theta/° valor d, recuentos (gamma = 1,5418L) 16,9, 5,2, 637; 11,8, 7,5, 1668; 14,3, 6,2, 1171.
ARP110101484A 2010-04-30 2011-04-28 Formas cristalinas polimorficas a y d de la sal mesilato de 7-metil-5(3-piperazin-1-ilmetil-[1,2,4]oxadiazol-5-il)-2-(4-trifluorometoxibencil)2,3-dihidroisoindol-1-ona,metodo para prepararlas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento del dolor y la ansied AR080987A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32966210P 2010-04-30 2010-04-30

Publications (1)

Publication Number Publication Date
AR080987A1 true AR080987A1 (es) 2012-05-23

Family

ID=44861775

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101484A AR080987A1 (es) 2010-04-30 2011-04-28 Formas cristalinas polimorficas a y d de la sal mesilato de 7-metil-5(3-piperazin-1-ilmetil-[1,2,4]oxadiazol-5-il)-2-(4-trifluorometoxibencil)2,3-dihidroisoindol-1-ona,metodo para prepararlas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento del dolor y la ansied

Country Status (15)

Country Link
US (1) US20130237548A1 (es)
EP (1) EP2563782A4 (es)
JP (1) JP2013525427A (es)
KR (1) KR20130094179A (es)
CN (1) CN102858766A (es)
AR (1) AR080987A1 (es)
AU (1) AU2011245737A1 (es)
BR (1) BR112012027628A2 (es)
CA (1) CA2795218A1 (es)
IL (1) IL222601A0 (es)
MX (1) MX2012012447A (es)
RU (1) RU2012144778A (es)
SG (1) SG184449A1 (es)
TW (1) TW201206913A (es)
WO (1) WO2011136723A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
CA2696948C (en) 2007-09-14 2013-04-30 Jose Maria Cid-Nunez 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones
KR20100080597A (ko) 2007-09-14 2010-07-09 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 1,3-이치환된-4-페닐-1h-피리딘-2-온
CA2735764C (en) 2008-09-02 2016-06-14 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
AU2009304293B2 (en) 2008-10-16 2012-04-26 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
BRPI0921333A2 (pt) 2008-11-28 2015-12-29 Addex Pharmaceuticals Sa derivados de indol e benzoxazina como moduladores de receptores de glutamato metabotrópicos
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
NZ596078A (en) 2009-05-12 2013-06-28 Janssen Pharmaceuticals Inc 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
EA020671B1 (ru) 2009-05-12 2014-12-30 Янссен Фармасьютикалз, Инк. ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2
CN103298810B (zh) 2010-11-08 2016-03-16 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CA2815002C (en) 2010-11-08 2019-10-22 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
LT3431106T (lt) 2014-01-21 2021-02-10 Janssen Pharmaceutica Nv Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
KR102414246B1 (ko) 2014-01-21 2022-06-27 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
KR200482429Y1 (ko) 2016-02-16 2017-01-23 이순호 막힘 해소장치를 갖는 양변기
GB2621323A (en) * 2022-08-03 2024-02-14 Sirgartan Holdings Ltd Treatments for obsessive compulsive disorder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070185095A1 (en) * 2004-02-18 2007-08-09 Astrazeneca Ab Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
TWI417100B (zh) * 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-842之用途
SG181958A1 (en) * 2010-01-07 2012-07-30 Astrazeneca Ab Process for making a metabotropic glutamate receptor positive allosteric modulator - 874

Also Published As

Publication number Publication date
WO2011136723A1 (en) 2011-11-03
EP2563782A4 (en) 2013-09-04
KR20130094179A (ko) 2013-08-23
AU2011245737A1 (en) 2012-12-20
TW201206913A (en) 2012-02-16
MX2012012447A (es) 2012-11-21
SG184449A1 (en) 2012-11-29
EP2563782A1 (en) 2013-03-06
CA2795218A1 (en) 2011-11-03
US20130237548A1 (en) 2013-09-12
IL222601A0 (en) 2012-12-31
JP2013525427A (ja) 2013-06-20
RU2012144778A (ru) 2014-06-10
BR112012027628A2 (pt) 2016-08-09
CN102858766A (zh) 2013-01-02

Similar Documents

Publication Publication Date Title
PH12021550792A1 (en) 2-(morpholin-4-yl)-1,7-naphthyridines
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
MX374729B (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4.
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
AR089554A1 (es) Formas cristalinas de un inhibidor de la dipeptidil peptidasa-iv
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
CR20160035A (es) Inhibidores de bromodominios
MX2016015248A (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
SG10201805628TA (en) Deuterated heterocyclic compounds and their use as imaging agents
CR20140399A (es) Pirrolidina-2-carboxamidas sustituidas
CO6781507A2 (es) Novedosos derivados heterociclicos
ECSP14013215A (es) Compuestos novedosos
TW201613864A (en) Novel compounds
MX354914B (es) Aminas biciclicas c-17 de triterpenoides con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana (vih).
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
UY36228A (es) Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen
GB201209587D0 (en) Therapeutic compounds
CR20130569A (es) Análogos del ácido epoxieicosatrienoicos y métodos de toma y uso del mismo
EA201600619A1 (ru) Хромен и 1,1а, 2,7в-тетрагидроциклопропа[с]хромен пиридопиразиндионы в качестве модулятора гамма-секретазы
PH12018500378B1 (en) Novel annelated phenoxyacetamides
ECSP16074482A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
TR201813294T4 (tr) N-aril-2-amino-4-aril-pirimidin makrosi̇kli̇k poli̇eter türevleri̇ ve bunlarin flt3 ve jak i̇nhi̇bi̇törleri̇ olarak kullanimlari.
PH12016501098A1 (en) Polymorphic and amorphous forms of cortisol 17-alpha-benzoate and methods for the preparation and use thereof
MX2017002747A (es) Derivados de polieteres macrociclicos de n-aril-triciclopirimidin- 2-amino como inhibidores de ftl3 y jak.
ECSP17003149A (es) Compuestos de dihidroisoquinolinona sustituida

Legal Events

Date Code Title Description
FB Suspension of granting procedure